AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30858255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 246
Study 29959443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention (2400 patients)
Number of subjects: 4800
Study 27903289 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) (2 mA/day, three times per week for 3 weeks)
Number of subjects: 16
Study 24777591 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of NOMAC/E2 (2.5/1.5 mg)
Number of subjects: 100
Study 24777591 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic dose of NOMAC/E2 (12.5/7.5 mg)
Number of subjects: 100
Study 24777591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24777591 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 100
Study 22565934 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised endurance training
Number of subjects: 60
Study 20384438 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 0
Study 20384438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18979976 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 719
Study 18979976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 719
Study 16477959 — intervention group
Group type: COMPARATOR
Intervention: Eszopiclone 2 mg
Number of subjects: 231
Study 16477959 — intervention group
Group type: COMPARATOR
Intervention: Eszopiclone 1 mg
Number of subjects: 231
Study 12742761 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview condition with several suggestive techniques
Number of subjects: 111
Study 12742761 — intervention group
Group type: COMPARATOR
Intervention: Interview condition with only suggestive questions
Number of subjects: 111
Study 10924966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation at 1.2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks
Number of subjects: 1113
Study 10924966 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field for the last 12 treatment days to 72 Gy/42 fractions/6 weeks
Number of subjects: 1113
Study 10924966 — intervention group
Group type: COMPARATOR
Intervention: Accelerated fractionation with split at 1.6 Gy/fraction, twice daily, 5 days/week to 67.2 Gy/42 fractions/6 weeks
Number of subjects: 1113
Study 10924966 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 Gy/35 fractions/7 weeks
Number of subjects: 1113
Study 8972541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.75 or 1.5 mg)
Number of subjects: 10
Study 8972541 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study 1462910 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 15
Study 1462910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1462910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 15
Study 6738359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 164
Study 6738359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (1 ounce)
Number of subjects: 164
Study 6738359 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater physical activity
Number of subjects: 164
Study 6738359 — intervention group
Group type: COMPARATOR
Intervention: Smokers who exercise or consume alcohol
Number of subjects: 164
Study 6738359 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who both exercise and consume alcohol
Number of subjects: 164
Study 30501824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration to women before elective cesarean section (group 1)
Number of subjects: 535
Study 30501824 — intervention group
Group type: COMPARATOR
Intervention: No steroid cover (group 2)
Number of subjects: 535
Study 27608829 — intervention group
Group type: EXPERIMENTAL
Intervention: PilAm Go4Health Weight Loss Program (intervention group, n=22)
Number of subjects: 45
Study 27608829 — intervention group
Group type: COMPARATOR
Intervention: Wait list active control (control group, n=23)
Number of subjects: 45
Study 24907062 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 1048
Study 24907062 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 1048
Study 24907062 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1048
Study 23072538 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice consumption (400 mL of blended juice of açai, camu‐camu, and blackberries)
Number of subjects: 12
Study 23072538 — intervention group
Group type: COMPARATOR
Intervention: Sugar solution (control)
Number of subjects: 12
Study 19499321 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based skills training and motivational intervention
Number of subjects: 112
Study 19499321 — intervention group
Group type: COMPARATOR
Intervention: Control website focusing on relaxation skills
Number of subjects: 112
Study 18538053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% w/v
Number of subjects: 54
Study 18538053 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% w/v
Number of subjects: 54
Study 16103764 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) plus stavudine (d4T)
Number of subjects: 509
Study 16103764 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not receiving ddI plus d4T)
Number of subjects: 509
Study 12421773 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose corticosteroid infusion for 48 hours after head injury
Number of subjects: 1000
Study 12421773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12198662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses
Number of subjects: 70
Study 9518395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day)
Number of subjects: 855
Study 9518395 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (1 or 2 insulin injections daily)
Number of subjects: 855
Study 9518395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 855
Study 7536209 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (120 micrograms/kg, sc, daily)
Number of subjects: 17
Study 7536209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 months) followed by rhIGF‐I (6 months)
Number of subjects: 17
Study 7536209 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 17
Study 2239785 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 micrograms)
Number of subjects: 80
Study 2239785 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin (10 mg)
Number of subjects: 80
Study 2239785 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic-acid-plus-thiamin
Number of subjects: 80
Study 2239785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 214218 — intervention group
Group type: COMPARATOR
Intervention: oral 5‐Fluorouracil (5FU)
Number of subjects: 168
Study 214218 — intervention group
Group type: EXPERIMENTAL
Intervention: oral 5‐Fu plus Streptozotocin
Number of subjects: 168
Study 214218 — intervention group
Group type: EXPERIMENTAL
Intervention: oral 5‐Fu plus Methyl‐CCNU
Number of subjects: 168
Study 214218 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 168
Study 7043345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (6 g intravenously immediately after delivery, with a second 3-g dose 6 to 8 hours after delivery for some patients)
Number of subjects: 259
Study 7043345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 7043345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (for high-risk patients)
Number of subjects: 259
Study 7043345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for high-risk patients)
Number of subjects: 259
Study 7043345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (for low-risk patients)
Number of subjects: 259
Study 7043345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for low-risk patients)
Number of subjects: 259
Study 30188912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39
Study 26074306 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone tinnitus education
Number of subjects: 0
Study 24626789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and family‐focused treatment (21 sessions over 9 months)
Number of subjects: 145
Study 24626789 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy and enhanced care (three weekly sessions of family psychoeducation)
Number of subjects: 145
Study 22001312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding and complementary feeding (5 sessions on breastfeeding and 1 session on complementary feeding)
Number of subjects: 323
Study 22001312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 323
Study 22001312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding
Number of subjects: 323
Study 20044231 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 11
Study 18367770 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 60
Study 18367770 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (24 microg)
Number of subjects: 60
Study 15846191 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief folic acid counseling, a reminder phone call, and 30 folic acid tablets (n = 162 women)
Number of subjects: 322
Study 15846191 — intervention group
Group type: COMPARATOR
Intervention: Counseling about other preventive health behaviors and a folic acid informational pamphlet (n = 160 women)
Number of subjects: 322
Study 12527539 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 25
Study 12527539 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 25
Study 10531630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone formulation 1
Number of subjects: 18
Study 10531630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone formulation 2
Number of subjects: 18
Study 10531630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone formulation 3
Number of subjects: 18
Study 10531630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone formulations (all)
Number of subjects: 18
Study 10531630 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 18
Study 8888599 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants urged to be honest
Number of subjects: 0
Study 8888599 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants urged to be polite
Number of subjects: 0
Study 8888599 — intervention group
Group type: EXPERIMENTAL
Intervention: No special instructions given
Number of subjects: 0
Study 8888599 — intervention group
Group type: EXPERIMENTAL
Intervention: Artists personally invested in paintings
Number of subjects: 0
Study 8888599 — intervention group
Group type: EXPERIMENTAL
Intervention: Artists not personally invested in paintings
Number of subjects: 0
Study 1984375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% isoflurane
Number of subjects: 21
Study 1984375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane
Number of subjects: 21
Study 1984375 — intervention group
Group type: COMPARATOR
Intervention: midazolam and fentanyl
Number of subjects: 21
Study 6366821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 68
Study 6366821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5.0 mg
Number of subjects: 68
Study 6366821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 68
Study 6366821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10.0 mg
Number of subjects: 68
Study 6366821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30700487 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational condition addressing knowledge, risk communication, and enhancing self-efficacy regarding vaccination
Number of subjects: 8875
Study 30700487 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity information condition
Number of subjects: 8875
Study 30318972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary water (250 mL)
Number of subjects: 80
Study 30318972 — intervention group
Group type: COMPARATOR
Intervention: Plain mineral water
Number of subjects: 80
Study 26894621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine‐impregnated washcloths used to wipe the patient's body once daily
Number of subjects: 481
Study 26894621 — intervention group
Group type: COMPARATOR
Intervention: Non‐antimicrobial soap (control group)
Number of subjects: 481
Study 26894621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine‐impregnated washcloths
Number of subjects: 481
Study 24463982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 29
Study 24463982 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 29
Study 24463982 — intervention group
Group type: COMPARATOR
Intervention: Placebo Oral Appliance (POA)
Number of subjects: 29
Study 22766993 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium light roast (MLR) coffee
Number of subjects: 20
Study 22766993 — intervention group
Group type: COMPARATOR
Intervention: Medium roast (MR) coffee
Number of subjects: 20
Study 20799923 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials (RCTs) for depression
Number of subjects: 150
Study 20799923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicaltrials.gov studies
Number of subjects: 150
Study 17513398 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain products (3 bread slices, 2 crisp bread slices, 1 portion muesli, and 1 portion pasta)
Number of subjects: 30
Study 17513398 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain products (3 bread slices, 2 crisp bread slices, 1 portion muesli, and 1 portion pasta)
Number of subjects: 30
Study 17513398 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain products
Number of subjects: 30
Study 17513398 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain products
Number of subjects: 30
Study 16194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-control multimedia learning environment courseware package (n = 15)
Number of subjects: 30
Study 16194247 — intervention group
Group type: COMPARATOR
Intervention: Program-control multimedia learning environment courseware package (n = 15)
Number of subjects: 30
Study 11820660 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculectomy (n = 40)
Number of subjects: 80
Study 11820660 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision trabeculectomy (SIT) avoiding Tenon's capsule (n = 40)
Number of subjects: 80
Study 10740301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethamsylate (12.5 mg/kg) six hourly for four days
Number of subjects: 192
Study 10740301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethamsylate)
Number of subjects: 192
Study 8753942 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (angry face) from male
Number of subjects: 0
Study 8753942 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (angry face) from female
Number of subjects: 0
Study 8753942 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (angry face from adult male)
Number of subjects: 0
Study 8753942 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ (happy face) from adult male
Number of subjects: 0
Study 1928663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromoglycate plus chlorphenamine
Number of subjects: 0
Study 1928663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromoglycate plus tetryzolin
Number of subjects: 0
Study 1928663 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazolin plus nafazolin
Number of subjects: 0
Study 1928663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7039401 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL 57787 18 mg x 4
Number of subjects: 35
Study 7039401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 28987824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led programme for comorbidities management, cost € 16,804.2
Number of subjects: 0
Study 27108827 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 63
Study 27108827 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq NT
Number of subjects: 63
Study 27108827 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 63
Study 24664177 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor (Civette, smelling like feces)
Number of subjects: 45
Study 24664177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor (Rose)
Number of subjects: 45
Study 24664177 — intervention group
Group type: COMPARATOR
Intervention: Odorless control condition
Number of subjects: 45
Study 22405475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (increased physical activity)
Number of subjects: 810
Study 22405475 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 810
Study 20136418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 2.5 mg (0.1 ml) bevacizumab
Number of subjects: 30
Study 20136418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 18477087 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH with oxygen insufflation
Number of subjects: 45
Study 18477087 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH with air insufflation
Number of subjects: 45
Study 18477087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 15981753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap
Number of subjects: 20
Study 15981753 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticare
Number of subjects: 20
Study 15981753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hewlett-Packard
Number of subjects: 20
Study 15981753 — intervention group
Group type: COMPARATOR
Intervention: Invasive blood pressure measurement (Hewlett-Packard invasive unit)
Number of subjects: 20
Study 12710787 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex-Guide (FG) Endotracheal Tube (ETT) introducer
Number of subjects: 96
Study 12710787 — intervention group
Group type: COMPARATOR
Intervention: Stylet ETT intubation
Number of subjects: 96
Study 10340796 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse treatment
Number of subjects: 66
Study 10340796 — intervention group
Group type: COMPARATOR
Intervention: Control (mecobalamin)
Number of subjects: 66
Study 8636344 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration (0.1 IU/kg x day)
Number of subjects: 8
Study 8636344 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 administration (40 microg on even dates, 20 microg on uneven dates)
Number of subjects: 8
Study 8636344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GH and T3 administration
Number of subjects: 8
Study 8636344 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections and placebo tablets
Number of subjects: 8
Study 1767711 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blockers (Ranitidine 300 mg or Famotidine 40 mg)
Number of subjects: 154
Study 1767711 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of H2 receptor antagonists or sucralfate (4 gr/day)
Number of subjects: 154
Study 1767711 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg, single dose
Number of subjects: 154
Study 1767711 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (ranitidine 150 mg or famotidine 20 mg)
Number of subjects: 154
Study 1767711 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 154
Study 6127150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 168
Study 6127150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg intravenously
Number of subjects: 168
Study 6127150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg intravenously
Number of subjects: 168
Study 6127150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally
Number of subjects: 168
Study 6127150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally
Number of subjects: 168
Study 6127150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 30875890 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-biased desk
Number of subjects: 99
Study 30875890 — intervention group
Group type: COMPARATOR
Intervention: Traditional desk
Number of subjects: 99
Study 28476273 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CHESS intervention (smartphone application and 8‐month service plan)
Number of subjects: 349
Study 28476273 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 349
Study 26241419 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 395
Study 26241419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 23611172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5mg/day for 2 weeks
Number of subjects: 78
Study 23611172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5mg/day for 2 weeks
Number of subjects: 78
Study 23611172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5mg/day continuation for 2 weeks
Number of subjects: 78